Riskpilot← Back to searchSign inGet full accessGLAXOSMITHKLINE AS
ASActiveOrg 930606308Drammensveien 288, 0283 OsloWholesale of pharmaceutical and medical goods · NACE 4646Est. 198179 employees
Revenue 2024
NOK 1B
+15% vs 2023
EBITDA margin
3.3%
+33% vs 2023
Equity ratio
37.3%
Financial strength
Net profit 2024
NOK 26,2M
+26% vs 2023
| Revenue | NOK 1B | +15% |
| EBITDA | NOK 33,8M | +33% |
| Net profit | NOK 26,2M | +26% |
| Total assets | NOK 316,7M | +8% |
| Equity | NOK 118,1M | +2% |
| Employees | 79 | — |
Legal name
GLAXOSMITHKLINE AS
Org number
930606308
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
25. august 1981
Share capital
—
Employees
79 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Address
Drammensveien 288, 0283 Oslo
Phone
+4722702000
Email
post@gsk.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2011 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 657 516 | 642 884 | 725 085 | 747 280 | 827 524 | 822 455 | 813 224 | 812 012 | 875 594 | 782 166 | 853 015 | 903 088 | 1 038 773 |
| Staff expenses | −130 733 | −0 | −111 318 | −100 444 | −76 602 | −82 387 | −0 | −88 225 | −0 | −0 | −0 | −0 | −0 |
| EBITDA | 44 843 | 33 658 | 38 328 | 23 397 | 20 466 | 30 057 | 30 530 | 25 695 | 27 531 | 28 190 | 27 072 | 25 435 | 33 829 |
| Depreciation & amort. | −4 428 | −4 417 | −2 879 | −2 715 | −2 634 | −2 561 | −1 965 | −1 749 | −1 751 | −1 754 | −1 463 | −6 | −483 |
| EBIT | 40 416 | 29 242 | 35 449 | 20 682 | 17 831 | 27 496 | 28 565 | 23 946 | 25 781 | 26 436 | 25 609 | 25 430 | 33 346 |
| Net financials | −3 311 | −1 203 | −2 726 | −5 165 | −1 123 | 4 008 | 3 699 | 4 987 | 2 122 | 2 708 | 2 340 | 2 360 | 1 537 |
| Profit before tax | 37 104 | 28 039 | 32 723 | 15 517 | 16 709 | 31 504 | 32 263 | 28 933 | 27 903 | 29 144 | 27 949 | 27 789 | 34 884 |
| Tax | 11 614 | −0 | 9 135 | 5 513 | 5 179 | 8 671 | −0 | 7 093 | −0 | −0 | −0 | −0 | −0 |
| Net profit | 25 491 | 19 564 | 23 587 | 10 004 | 11 529 | 22 833 | 24 001 | 21 840 | 21 013 | 22 077 | 21 143 | 20 697 | 26 172 |
| Item | 2011 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 444 205 | 521 708 | 477 564 | 309 600 | 279 193 | 345 559 | 329 062 | 340 745 | 348 871 | 341 506 | 272 133 | 292 017 | 316 729 |
| Equity | 64 734 | 106 309 | 57 431 | 74 211 | 81 417 | 93 951 | 114 821 | 114 821 | 115 430 | 115 799 | 116 287 | 116 287 | 118 102 |
| Long-term debt | 219 000 | 219 000 | 219 000 | 59 000 | 0 | 0 | 2 642 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 119 511 | 165 031 | 163 373 | 154 402 | 182 967 | 231 552 | 211 599 | 225 924 | 233 441 | 225 707 | 155 846 | 175 730 | 198 628 |
| Total debt | 338 511 | 384 031 | 382 373 | 213 402 | 182 967 | 231 552 | 214 241 | 225 924 | 233 441 | 225 707 | 155 846 | 175 730 | 198 628 |
EBITDA margin
3.3%
This company
15.8%
Market median
-79% vs market
20112024
Equity ratio
37.3%
This company
38.2%
Market median
+2% vs market
20112024
Return on equity
22.2%
This company
18.4%
Market median
+21% vs market
20112024
Net profit margin
2.5%
This company
8.1%
Market median
-69% vs market
20112024
Asset turnover
3.28×
This company
1.12×
Market median
+193% vs market
20112024
Debt / equity
1.68×
This company
0.62×
Market median
-171% vs market
20112024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AE Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
CP Chief Executive Officer | Chief Executive Officer | 2015 | — | — |
OA Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2023 | — | — | |
| Chairman | 2022 | — | — | |
| Chairman | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Glaxosmithkline Holding As | Company | 100.0% | 100.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Glaxosmithkline Holding As
GLAXOSMITHKLINE AS Board members of GLAXOSMITHKLINE AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Akalin Erin Omur | Chief Executive Officer | 0 companies |
| Christian Probst | Chief Executive Officer | 0 companies |
| Omur Akalin Erin | Chief Executive Officer | 0 companies |
| Tetiana Luczkiw | Board of Directors | 0 companies |
| Paolo Chiesa | Board of Directors | 0 companies |
| Patrick Gerard Connor | Chairman | 0 companies |
| Anne Margareth Belcher | Chairman | 0 companies |